BFM
AIMT

Boothbay Fund Management’s Aimmune Therapeutics AIMT Stock Holding History

Boothbay Fund Management’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-6,640
Closed -$222K – 1184
2019
Q4 		$222K Sell
6,640
-19,360
-74% -$541K 0.02% 682
2019
Q3 		$544K Buy
+26,000
New +$531K 0.05% 442

Boothbay Fund Management's AIMT Position: Q1 2020 in Review

Boothbay Fund Management sold out of Aimmune Therapeutics (AIMT) in Q1 2020, closing a stake of 6,640 shares — an estimated $222K sold.

Boothbay Fund Management first reported a position in AIMT in Q3 2019 and held it in 2 quarters. The position peaked at $544K in Q3 2019. 161 funds tracked by Wall St. Rank hold AIMT as of Q1 2020.

  • Boothbay Fund Management reported no remaining Aimmune Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Boothbay Fund Management sold 6,640 Aimmune Therapeutics shares in Q1 2020, an estimated $222K.
  • Boothbay Fund Management first reported a position in Aimmune Therapeutics in Q3 2019 and held it in 2 quarters.
  • Boothbay Fund Management's Aimmune Therapeutics position peaked at $544K in Q3 2019.
  • 161 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q1 2020.

Based on Boothbay Fund Management's 13F filing for Q1 2020, filed 15 May 2020.